DOSING: The usual dose of medroxyprogesterone tablets is 5 or 10 mg daily.
- Secondary amenorrhea is treated for 5 to 10 days.
- Uterine bleeding is treated for 5 to 10 days beginning on day 16 or 21 of the menstrual cycle.
- Endometrial hyperplasia is treated for 12 to 14 consecutive days beginning on day 1 or 16 of the menstrual cycle.
- The dose for contraception is 150 mg every 3 months injected intramuscularly or 104 mg injected subcutaneously every 3 months.
- The dose for endometrial or renal cancer is 400-1000 mg weekly initially followed by monthly maintenance doses.
DRUG INTERACTIONS: Aminoglutethimide (Cytadren) may increase the elimination of medroxyprogesterone by the liver leading to a decrease in the concentration of medroxyprogesterone in blood and possibly a reduction in the effectiveness of the medroxyprogesterone.
PREGNANCY: Medroxyprogesterone inhibits fertility at high doses. It should not be given during pregnancy.
NURSING MOTHERS: Medroxyprogesterone is secreted in breast milk. The effect on the infant has not been determined.
SIDE EFFECTS: Breast tenderness and leakage of liquid from the nipple occur rarely with medroxyprogesterone. Various skin reactions, including hives, acne, hair growth and hair loss, also have been reported occasionally. Break-through bleeding (menstrual-like bleeding in the middle of the menstrual cycle), vaginal spotting of blood, changes in menstrual flow, increased or decreased weight, nausea, fever, insomnia, and jaundice have all been reported.
Quick GuideMenopause & Perimenopause: Symptoms, Signs
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.